User profiles for Aparna Mukherjee

Aparna Mukherjee

- Verified email at icmr.gov.in - Cited by 2582

APARNA MUKHERJEE

- Verified email at phd.nitdgp.ac.in - Cited by 224

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

A Agarwal, A Mukherjee, G Kumar, P Chatterjee… - bmj, 2020 - bmj.com
Objective To investigate the effectiveness of using convalescent plasma to treat moderate
coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm, phase …

Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus

…, J Peng, P Swiatkowski, A Mukherjee… - Journal of …, 2014 - Soc Neuroscience
Microglia are highly dynamic immune cells of the CNS and their dynamism is proposed to be
regulated by neuronal activities. However, the mechanisms underlying neuronal regulation …

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial

…, F Ruggiero, DT Mauger, A Mukherjee… - Digestive diseases and …, 2011 - Springer
Background Endogenous opioid peptides have been shown to play a role in the development
and/or perpetuation of inflammation. We hypothesize that the endogenous opioid system …

Clinical profile of hospitalized COVID-19 patients in first & second wave of the pandemic: Insights from an Indian registry based observational study

G Kumar, A Mukherjee, RK Sharma… - Indian Journal of …, 2021 - journals.lww.com
Methods: The NCRC, launched in September 2020, is an ongoing multicentre observational
initiative, which provided the platform for the current investigation. Demographic, clinical, …

Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis

…, G Meyfroidt, AM Nicola, A Mukherjee… - JAMA Network …, 2022 - jamanetwork.com
Importance COVID-19 convalescent plasma (CCP) is a potentially beneficial treatment for
COVID-19 that requires rigorous testing. Objective To compile individual patient data from …

Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may benefit from convalescent plasma

…, G Meyfroidt, AM Nicola, A Mukherjee… - JAMA network …, 2022 - jamanetwork.com
Importance Identifying which patients with COVID-19 are likely to benefit from COVID-19
convalescent plasma (CCP) treatment may have a large public health impact. Objective To …

SARS-CoV-2 re-infection: development of an epidemiological definition from India

A Mukherjee, T Anand, A Agarwal, H Singh… - Epidemiology & …, 2021 - cambridge.org
The current investigation was conducted with the objective to develop an epidemiological
case definition of possible severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) re-…

Aggression in sexually abused trafficked girls and efficacy of intervention

S Deb, A Mukherjee, B Mathews - Journal of interpersonal …, 2011 - journals.sagepub.com
The broad objective of this study was to understand the incidence and severity of aggression
among sexually abused girls who were trafficked and who were then further used for …

Xpert MTB/RIF assay can be used on archived gastric aspirate and induced sputum samples for sensitive diagnosis of paediatric tuberculosis

…, S Prajapati, SK Kabra, R Lodha, A Mukherjee… - BMC microbiology, 2015 - Springer
Background Tuberculosis (TB) in children is neglected, mainly due to lack of sensitive
diagnostic tools. Recently Xpert MTB/RIF assay has revolutionized the diagnostic field, but its …

[HTML][HTML] Parametric optimization of delignification of rice straw through central composite design approach towards application in grafting

A Mukherjee, S Banerjee, G Halder - Journal of Advanced Research, 2018 - Elsevier
The present investigation deals with process optimisation of delignification of rice straw
towards its micro-porous structural enhancement for its utilization in polymer grafting. The …